Editas Medicine Inc (DE:8EM)
FRANKFURT:8EM
Holding DE:8EM?
Track your performance easily

Editas Medicine (8EM) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

8EM Analyst Ratings

Moderate Buy
11Ratings
6 Buy
5 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Editas
Medicine
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

8EM Stock 12 Month Forecast

Average Price Target

€9.97
▲(246.16% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is €9.97 with a high forecast of €16.32 and a low forecast of €6.35. The average price target represents a 246.16% change from the last price of €2.88.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","5":"€5","9":"€9","13":"€13","17":"€17"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.31916,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€16.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.97282,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€9.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.34634,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.35</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5,9,13,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"Apr<br/>2024","9":"Jul<br/>2024","12":"Oct<br/>2024","25":"Oct<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.881,3.9147046153846152,4.948409230769231,5.982113846153846,7.015818461538462,8.049523076923077,9.083227692307693,10.116932307692307,11.150636923076924,12.184341538461538,13.218046153846155,14.251750769230771,15.285455384615386,{"y":16.31916,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.881,3.426524615384615,3.9720492307692306,4.517573846153846,5.063098461538461,5.608623076923077,6.154147692307692,6.699672307692307,7.245196923076923,7.790721538461538,8.336246153846155,8.88177076923077,9.427295384615384,{"y":9.97282,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.881,3.1475646153846153,3.4141292307692304,3.680693846153846,3.9472584615384614,4.213823076923077,4.480387692307692,4.7469523076923075,5.0135169230769225,5.2800815384615385,5.5466461538461544,5.8132107692307695,6.079775384615385,{"y":6.34634,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.79,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.51,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.59,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.23,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.258,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.292,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.784,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.081,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.543,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.984,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.881,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€16.32Average Price Target€9.97Lowest Price Target€6.35
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Robert W. Baird
€16.32
Buy
466.44%
Upside
Reiterated
08/07/24
Buy Rating for Editas Medicine Backed by Strong Q2 Performance and Promising CRISPR Pipeline
Oppenheimer
€10.88
Hold
277.63%
Upside
Reiterated
06/18/24
Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), GeoVax Labs (NASDAQ: GOVX) and Editas Medicine (NASDAQ: EDIT)
Wells Fargo
Buy
Reiterated
06/14/24
Editas Medicine (EDIT) Receives a Buy from Wells Fargo
J.P. Morgan
€7.25€8.16
Hold
183.22%
Upside
Reiterated
02/27/24
Editas Medicine (EDIT) PT Raised to $9 at JPMorganJPMorgan analyst Brian Cheng raised the price target on Editas Medicine (NASDAQ: EDIT) to $9.00 (from $8.00) while maintaining a Neutral rating.
Chardan Capital
€18.13
Buy
529.38%
Upside
Reiterated
12/13/23
Buy Rating Affirmed for Editas Medicine Amid Strategic Partnerships and Promising Treatment Data

Best Analysts Covering Editas Medicine

Which Analyst Should I Follow If I Want to Buy DE:8EM and Sell After:
1 Month
xxx
Success Rate
12/34 ratings generated profit
35%
Average Return
+2.77%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 35.29% of your transactions generating a profit, with an average return of +2.77% per trade.
3 Months
xxx
Success Rate
13/34 ratings generated profit
38%
Average Return
-1.48%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 38.24% of your transactions generating a profit, with an average return of -1.48% per trade.
1 Year
Geulah LivshitsChardan Capital
Success Rate
14/34 ratings generated profit
41%
Average Return
-6.60%
reiterated a buy rating 10 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of -6.60% per trade.
2 Years
xxx
Success Rate
7/13 ratings generated profit
54%
Average Return
+28.74%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 53.85% of your transactions generating a profit, with an average return of +28.74% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

8EM Analyst Recommendation Trends

Rating
Mar 24
May 24
Jun 24
Aug 24
Sep 24
Strong Buy
4
5
4
8
6
Buy
3
3
2
2
2
Hold
7
13
11
16
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
21
17
26
18
In the current month, 8EM has received 8 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. 8EM average Analyst price target in the past 3 months is €9.97.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

8EM Financial Forecast

8EM Earnings Forecast

Next quarter’s earnings estimate for 8EM is -€0.71 with a range of -€0.87 to -€0.40. The previous quarter’s EPS was -€0.74. 8EM beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 55.77% of the time in the same period. In the last calendar year 8EM has Underperformed its overall industry.
Next quarter’s earnings estimate for 8EM is -€0.71 with a range of -€0.87 to -€0.40. The previous quarter’s EPS was -€0.74. 8EM beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 55.77% of the time in the same period. In the last calendar year 8EM has Underperformed its overall industry.

8EM Sales Forecast

Next quarter’s sales forecast for 8EM is €3.55M with a range of €0.00 to €24.84M. The previous quarter’s sales results were €463.29K. 8EM beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 53.23% of the time in the same period. In the last calendar year 8EM has Underperformed its overall industry.
Next quarter’s sales forecast for 8EM is €3.55M with a range of €0.00 to €24.84M. The previous quarter’s sales results were €463.29K. 8EM beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 53.23% of the time in the same period. In the last calendar year 8EM has Underperformed its overall industry.

8EM Stock Forecast FAQ

What is DE:8EM’s average 12-month price target, according to analysts?
Based on analyst ratings, Editas Medicine Inc’s 12-month average price target is €9.97.
    What is DE:8EM’s upside potential, based on the analysts’ average price target?
    Editas Medicine Inc has 246.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Editas Medicine Inc a Buy, Sell or Hold?
          Editas Medicine Inc has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Editas Medicine Inc’s share price target?
            The average share price target for Editas Medicine Inc is €9.97. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €16.32 ,and the lowest forecast is €6.35. The average share price target represents 246.16% Increase from the current price of €2.881.
              What do analysts say about Editas Medicine Inc?
              Editas Medicine Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of Editas Medicine Inc?
                To buy shares of DE:8EM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis